High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.
作者信息
Fichtenbaum Carl J, Evans Scott E, Aberg Judith A
出版信息
AIDS. 2011 Oct 23;25(16):2053. doi: 10.1097/QAD.0b013e32834b9680.
Abstract
摘要
相似文献
1
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.在所有感染HIV的人群中，使用他汀类药物并不会使高敏C反应蛋白水平降低。
AIDS. 2011 Oct 23;25(16):2053. doi: 10.1097/QAD.0b013e32834b9680.
2
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.在接受利托那韦增强蛋白酶抑制剂治疗的 HIV 感染患者中，辛伐他汀治疗期间 C 反应蛋白水平降低。
AIDS. 2011 May 15;25(8):1128-31. doi: 10.1097/QAD.0b013e328346be29.
3
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.他汀类药物治疗对C反应蛋白水平的影响：普伐他汀炎症/C反应蛋白评估（PRINCE）：一项随机试验和队列研究。
JAMA. 2001 Jul 4;286(1):64-70. doi: 10.1001/jama.286.1.64.
4
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.在接受蛋白酶抑制剂治疗的血脂异常 HIV-1 感染患者中，瑞舒伐他汀与普伐他汀的比较：一项随机试验。
AIDS. 2010 Jan 2;24(1):77-83. doi: 10.1097/QAD.0b013e328331d2ab.
5
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.普伐他汀和非诺贝特治疗可改善 ACTG 5087 中的致动脉粥样硬化脂质谱，但不能改善炎症标志物。
J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.
6
The PROSPER trial.
Lancet. 2003 Feb 1;361(9355):427; author reply 428.
7
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.HIV 感染者中他汀类药物的比较疗效和毒性。
Clin Infect Dis. 2011 Feb 1;52(3):387-95. doi: 10.1093/cid/ciq111. Epub 2010 Dec 28.
8
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.依折麦布与普伐他汀在 HIV-1 感染伴血脂异常成人患者中的应用（INTREPID）：一项 4 期、多中心、随机、双盲、优效性临床试验的 12 周和 52 周结果。
Lancet HIV. 2017 Jul;4(7):e284-e294. doi: 10.1016/S2352-3018(17)30075-9. Epub 2017 Apr 13.
9
The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.他汀类药物治疗 HIV 血脂异常的安全性和有效性：迄今为止的证据和未来的挑战。
Expert Opin Pharmacother. 2012 Sep;13(13):1901-9. doi: 10.1517/14656566.2012.706604. Epub 2012 Jul 7.
10
The role of statins in the setting of HIV infection.他汀类药物在HIV感染情况下的作用。
Curr HIV/AIDS Rep. 2015 Sep;12(3):305-12. doi: 10.1007/s11904-015-0273-9.
引用本文的文献
1
Benefits and Risks of Statin Therapy in the HIV-Infected Population.他汀类药物治疗在HIV感染人群中的益处与风险
Curr Infect Dis Rep. 2018 May 26;20(8):20. doi: 10.1007/s11908-018-0628-7.
2
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.阿托伐他汀在感染人类免疫缺陷病毒的高脂血症儿童、青少年及青年中的安全性和有效性
Pediatr Infect Dis J. 2017 Jan;36(1):53-60. doi: 10.1097/INF.0000000000001352.
3
Statins to improve cardiovascular outcomes in treated HIV infection.他汀类药物改善接受治疗的HIV感染患者的心血管结局。
Curr Opin Infect Dis. 2016 Feb;29(1):1-9. doi: 10.1097/QCO.0000000000000223.
4
The role of statins in the setting of HIV infection.他汀类药物在HIV感染情况下的作用。
Curr HIV/AIDS Rep. 2015 Sep;12(3):305-12. doi: 10.1007/s11904-015-0273-9.
本文引用的文献
1
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.在接受利托那韦增强蛋白酶抑制剂治疗的 HIV 感染患者中，辛伐他汀治疗期间 C 反应蛋白水平降低。
AIDS. 2011 May 15;25(8):1128-31. doi: 10.1097/QAD.0b013e328346be29.
2
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.普伐他汀和非诺贝特治疗可改善 ACTG 5087 中的致动脉粥样硬化脂质谱，但不能改善炎症标志物。
J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.
Zotero 插件